Abstract
To the Editor.— After more than a year's delay, Dr Crout, the Director of the Bureau of Drugs of the Food and Drug Administration (FDA) has responded (234:480, 1975) to my editorial (229:689, 1974) on the drug lag in introducing new antihypertensive agents in the United States. My editorial was in reference to an article in the same issue ofThe Journal(229:693,1974) by Dr William O'Brien, a British physician who was writing on the treatment of hypertension. Among other drugs, Dr O'Brien advocated the use of bethanidine, debrisoquine, and propranolol, which are either not available or do not have labeling approved to recommend use in hypertension in this country. The expressed purpose of Dr Crout's letter was to correct alleged inaccuracies in the editorial, including my criticism of the delay by the FDA in approving these drugs. My actual statement was as follows: Applications for approval of these drugs
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
